These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 31345226)

  • 1. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
    Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis.
    Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier GC; Verazza S; Giancane G; Consolaro A; Ravelli A
    Clin Exp Rheumatol; 2021; 39(2):426-433. PubMed ID: 33200734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era.
    Giancane G; Muratore V; Marzetti V; Quilis N; Benavente BS; Bagnasco F; Alongi A; Civino A; Quartulli L; Consolaro A; Ravelli A
    Arthritis Res Ther; 2019 Jul; 21(1):168. PubMed ID: 31287015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
    van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
    Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.
    Kostik MM; Gaidar EV; Hynnes AY; Dubko MF; Masalova VV; Snegireva LS; Chikova IA; Isupova EA; Nikitina TN; Serogodskaya ED; Kalashnikova OV; Ravelli A; Chasnyk VG
    Clin Exp Rheumatol; 2016; 34(4):714-8. PubMed ID: 27385618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis.
    Papadopoulou C; Kostik M; Böhm M; Nieto-Gonzalez JC; Gonzalez-Fernandez MI; Pistorio A; Martini A; Ravelli A
    J Pediatr; 2013 Sep; 163(3):879-84. PubMed ID: 23664559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
    Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
    J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
    Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
    J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
    Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
    Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
    Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
    Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
    Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.
    van Dijkhuizen EH; Wulffraat NM
    Pediatr Rheumatol Online J; 2014; 12():51. PubMed ID: 25525416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
    Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
    Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
    Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis.
    Zajc Avramovič M; Dolžan V; Toplak N; Accetto M; Lusa L; Avčin T
    J Rheumatol; 2017 Aug; 44(8):1216-1223. PubMed ID: 28572465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.